{
    "clinical_study": {
        "@rank": "97418", 
        "acronym": "SCI-COG", 
        "arm_group": [
            {
                "arm_group_label": "Patient", 
                "arm_group_type": "Experimental", 
                "description": "Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Experimental", 
                "description": "healthy subject"
            }
        ], 
        "brief_summary": {
            "textblock": "Clinically isolated demyelinating syndromes (CIS) can evolve into multiple sclerosis (MS).\n      Cognitive deficiencies could occur at this early stage and concern mainly information\n      processing speed (IPS) and their mechanisms are not fully understood. Diffusion Tensor\n      Imaging (DTI) can help in the understanding of these mechanisms."
        }, 
        "brief_title": "Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Clinically Isolated Demyelinating Syndromes", 
            "Multiple Sclerosis", 
            "Cognitive Deficiencies", 
            "Brain MRI"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective cohort, observational, longitudinal, monocentric study. This study\n      will include 60 patients with CIS followed for 1 year and 60 healthy subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients:\n\n               -  Men and Women\n\n               -  \u226516 years\n\n               -  Fluent French speaker\n\n               -  Clinically isolated neurological syndrome (CIS) compatible with a demyelinating\n                  inflammatory episode within the central nervous system, potentially beginning\n                  multiple sclerosis (MS) whatever the mode of presentation\n\n               -  Between 60 and 180 days from the onset\n\n               -  At least two clinically silent lesions on their T2-weighted brain or spinal MRI\n                  scan with a size of at least 3 mm, at least one of which being cerebral, ovoid,\n                  or periventricular\n\n               -  Having a medical insurance\n\n               -  Free and informed consent signed\n\n          -  Controls:\n\n               -  Men and Women\n\n               -  \u226518 years\n\n               -  Fluent French speaker\n\n               -  Having a medical insurance\n\n               -  Free and informed consent signed\n\n        Exclusion Criteria:\n\n          -  Patients:\n\n               -  Prior documented neurological episode suggestive of MS.\n\n               -  Other ongoing neurological diseases.\n\n               -  Known chronic systemic diseases as judged by the investigator (for instance:\n                  lupus, Gougerot-Sj\u00f6gren, sarcoidosis, sclerodermia, Crohn disease,\u2026).\n\n               -  Other causes (trauma, tumor, radiotherapy, infections, vascular diseases,\n                  neuromyelitis optica).\n\n               -  Current dependence on alcohol or drugs.\n\n               -  Dosage change, stop or start of  hypnotic or anxiolytic or antidepressive\n                  treatment less than 15 days\n\n               -  MRI contra-indications.\n\n               -  Steroid treatment less than one month (be taken orally or by infusion) at the\n                  dosage of 500mg daily.\n\n          -  Controls:\n\n               -  Known chronic psychiatric or neurologic diseases which could interfere with\n                  neuropsychological testing, not taking into account stable and mild depressive\n                  syndrome\n\n               -  Known chronic systemic diseases as judged by the investigator (for instance:\n                  lupus, Gougerot-Sj\u00f6gren, sarcoidosis, scleroderma, Crohn disease\u2026).\n\n               -  MS familial history\n\n               -  Current dependence on alcohol or drugs\n\n               -  Known cognitive impairment\n\n               -  Prior neuropsychological testing with the same tests less than one year\n\n               -  Dosage change, stop or start of  hypnotic or anxiolytic or antidepressive\n                  treatment less than 2 months\n\n               -  Steroid treatment less than one month (be taken orally or by infusion) at the\n                  dosage of 500mg daily.\n\n               -  MRI contra-indications\n\n               -  Steroid treatment less than one month (be taken orally or by infusion) at the\n                  dosage of 500mg daily."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865357", 
            "org_study_id": "CHUBX 2011/33"
        }, 
        "intervention": {
            "arm_group_label": [
                "Patient", 
                "Control"
            ], 
            "description": "Clinical evaluation (EDSS, MSFC)\nCognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)\nBrain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI", 
            "intervention_name": "Brain MRI - Clinical and cognitive evaluation", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "bruno.brochet@chu-bordeaux.fr", 
                "last_name": "Bruno BROCHET, Prof", 
                "phone": "05 56 79 55 21"
            }, 
            "facility": {
                "address": {
                    "city": "Bordeaux", 
                    "country": "France", 
                    "zip": "33000"
                }, 
                "name": "CHU de Bordeaux"
            }, 
            "investigator": [
                {
                    "last_name": "Aur\u00e9lie RUET, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mathilde POLI, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Pierre LOUISET, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jean-Christophe OUALLET, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yvania PATRY, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI:\"SCI-COG\" Study", 
        "overall_contact": {
            "email": "bruno.brochet@chu-bordeaux.fr", 
            "last_name": "Bruno Brochet, Prof", 
            "phone": "05 56 79 55 21"
        }, 
        "overall_official": {
            "affiliation": "CHU - Bordeaux", 
            "last_name": "Bruno BROCHET, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "IPS, attention, working memory, episodic memory and executive functions), established by voxel-wise statistics (TBSS) in CIS patients", 
            "measure": "Correlation between fractional anisotropy (FA) value and cognitive z scores or cognitive impairment indexes for each domains", 
            "safety_issue": "No", 
            "time_frame": "visit 2 - 1 year after inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865357"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Comparison of skeleton of FA between CIS patients and healthy subjects", 
                "safety_issue": "No", 
                "time_frame": "V2 - 1 year after the inclusion"
            }, 
            {
                "measure": "Comparison of cognitive scores at each test between CIS patients and controls", 
                "safety_issue": "No", 
                "time_frame": "D0 and V2 - 1 year after the inclusion"
            }, 
            {
                "measure": "Proportion of patients with cognitive impairment (\u2265 3 tests impaired) and correlations with anxiety, depressive syndrome and fatigue", 
                "safety_issue": "No", 
                "time_frame": "D0 and V2 - 1 year after the inclusion"
            }, 
            {
                "description": "mean cortical thickness and deep grey nuclei volumes with cognitive indexes in  the 3 pre-define groups: cognitively preserved  CIS patients at baseline and after one year; cognitively impaired CIS patients only after one year and cognitively impaired CIS patients at the two evaluations.", 
                "measure": "Comparison of statistical maps of FA", 
                "safety_issue": "No", 
                "time_frame": "D0 and V2 - 1 year after the inclusion"
            }, 
            {
                "measure": "Correlations between cognitive scores and mean cortical thickness and deep grey nuclei volumes in CIS patients", 
                "safety_issue": "No", 
                "time_frame": "D0 and V2 - 1 year after the inclusion"
            }
        ], 
        "source": "University Hospital, Bordeaux", 
        "sponsors": {
            "collaborator": {
                "agency": "TEVA laboratories", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Bordeaux", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}